Brief: Bajaj Healthcare Gets SEC-Cdsco Nod For Phase III Clinical Trials For Cenobamate Tablets
19/03/2025 06:35
March 19 (Reuters) - Bajaj Healthcare Ltd BAJH.NS: BAJAJ HEALTHCARE LTD - RECEIVES SEC-CDSCO NOD FOR PHASE III CLINICAL TRIALS FOR CENOBAMATE TABLETS Source text: ID:nNSE7zRCQd Further company coverage: BAJH.NS ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Bajaj Healthcare
See all newsBrief: Bajaj Healthcare Ltd Posts March-Quarter Loss 228.5 Million Rupees
Brief: Bajaj Healthcare Posts Dec-Quarter Profit Of 156.7 Million Rupees
Brief: Bajaj Healthcare Receives CDSCO Approval For Suvorexant Tablets Trial
India's Bajaj Healthcare rises as insomnia pill trial gets regulatory nod
Brief: Bajaj Healthcare Posts June-Quarter Profit Of 118.3 Million Rupees